The introduction of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable interest within the healthcare community. This novel dual GIP and GLP-1 receptor medication seems to offer notable improvements in weight loss compared to current therapies. Initial patient trials have shown sign